Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: FLARE

Revised Retinopathy Screening Guidelines State Risks Linked to Hydroxychloroquine, Chloroquine

Vanessa Caceres  |  November 16, 2016

A large medical specialty society for ophthalmologists recently updated its recommendations for the screening of chloroquine (CQ) and hydroxychloroquine (HCQ) retinopathy.1 The recommendations from the American Academy of Ophthalmology (AAO) affect patients who may use CQ or HCQ for rheumatoid arthritis or systemic lupus erythematosus (SLE), as well as some inflammatory and dermatologic conditions. The…

Filed under:Conditions Tagged with:American Academy of OphthalmologychloroquineeyeguidelineHYDROXYCHLOROQUINEocularpatient carerecommendationretinopathyrheumatologistriskscreeningusagevision

New Treatment Guidelines to Be Presented at the 2016 ACR/ARHP Annual Meeting

Thomas R. Collins  |  October 27, 2016

Two sets of guidelines—one on managing anti-rheumatic drugs perioperatively for patients undergoing total hip and knee replacements, and another that updates glucocorticoid-induced osteoporosis prevention and treatment strategies—will be featured in sessions at the 2016 ACR/ARHP Annual Meeting this month. The Sessions Sunday, Nov. 13, 2:30–3:30 p.m.: Glucocorticoid-Induced Osteoporosis Prevention and Treatment: A New ACR Clinical…

Filed under:ConditionsOsteoarthritis and Bone DisordersProfessional Topics Tagged with:2016 ACR/ARHP Annual Meetinganti-rheumatic drugsBiologicsGlucocorticoid-Induced OsteoporosisOsteoporosistreatment guidelines

Tocilizumab Designated as Breakthrough Therapy for GCA

Michele B. Kaufman, PharmD, BCGP  |  October 26, 2016

To speed the development of tocilizumab to treat giant cell arteritis (GCA), the FDA designated it as a breakthrough therapy earlier this month…

Filed under:ConditionsDrug UpdatesGout and Crystalline Arthritis Tagged with:FDAFood and Drug AdministrationGiant Cell Arteritisgiant cell arteritis (GCA)Gouthyperuricemialesinuradtocilizumab

Tacrolimus Use for Lupus Nephritis Raises Debate over Role in North American Population

Alexey Fomin, MD, & W. Neal Roberts, MD  |  October 10, 2016

The following summary regarding use of tacrolimus (TAC) in lupus nephritis highlights a number of debatable points. Although the role of TAC in lupus nephritis remains unproved for North American populations, it might be an excellent option in some clinical situations. These situations include lupus flare during pregnancy and also for lupus nephritis when the…

Filed under:ConditionsResearch RheumSystemic Lupus Erythematosus Tagged with:Lupus nephritispatient carepopulationpregnancyResearchrheumatologyriskSLEtacrolimustherapy

Rheumatology Coding Corner Question: Gout Visit for Established Patient

From the College  |  October 10, 2016

A 55-year-old female patient returns to the office with complaints of gout pain. She is complaining of swelling and a burning pain in her left toe. She has been taking an over-the-counter NSAID to treat the pain, but this has done little to alleviate it. This is her second flare this year. The patient denies…

Filed under:Billing/CodingConditionsFrom the CollegeGout and Crystalline ArthritisOther Rheumatic ConditionsPractice Support Tagged with:BillingCodingGoutoffice visitpatient carePractice Managementrheumatologistrheumatology

Gout Treatment & Care Remain Suboptimal

Lara C. Pullen, PhD  |  September 12, 2016

A recent analysis compared the care of patients with RA with that received by patients with gout, finding that hospitalization and costs for patients with gout have increased, but both are decreasing for patients with RA. Unlike RA, significant advances in treatment have not been made for gout, despite its increasing prevalence, and patients may land in the hospital unnecessarily…

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:costsGouthospitalizedhyperuricemiapatient educationpatient outcomeRheumatoid Arthritis (RA)Treatment

Chronic Reactive Arthritis Secondary to Intravesical Bacillus Calmette–Guerin in Bladder Carcinoma

Derick N. Jenkins, MD, Josna Haritha, MD, & Huzaefah Syed, MD  |  September 8, 2016

A 50-year-old man with history of superficial bladder carcinoma presented to our rheumatology clinic for a three-year history of symmetric polyarthralgias. He had undergone multiple transurethral resection of bladder tumor procedures and bacillus Calmette–Guerin (BCG) treatments. Prior to receiving BCG, he was fully functional and employed. Days after receiving his second BCG treatment, he developed…

Filed under:Conditions Tagged with:case reportClinicalDiagnosisoutcomepatient careReactive arthritisrheumatologistTreatment

The Patient's Choice

When Rheumatologists Are a Patient’s Second or Third Choice for Medical Opinion

Charles Radis, DO  |  September 7, 2016

Outside Exam Room No. 5, the chart rack was empty, so I assumed my new consult was late. Just in case, I looked back over my shoulder as I passed by the partially open door and glimpsed the lower half of a woman holding a three-ringed binder on her lap. I squinted and took a…

Filed under:ConditionsPractice SupportPsoriatic Arthritis Tagged with:ArthritisLyme Diseasepatient carePractice ManagementPsoriatic ArthritisRheumatic Diseaserheumatologist

Treatment Options for Severe Refractory Gout When Pegloticase Fails

Diana M. Girnita, MD, PhD, Cody Lee, MD, & Christine Chhakchhuak, MD  |  August 12, 2016

Pegloticase is a new alternative therapy for patients with severe, refractory gout unresponsive to other urate-lowering agents. The goal of this therapy is to reduce disease burden, tophi size and frequency of flares and to improve quality of life when other treatments have failed. Persistent lowering of plasma uric acid (PUA) to less than 6…

Filed under:ConditionsGout and Crystalline ArthritisResearch Rheum Tagged with:ClinicalGoutoutcomepegloticaseResearchrheumatologistrheumatologyTreatment

New Criteria Released for Macrophage Activation Syndrome in Juvenile Idiopathic Arthritis

Susan Bernstein  |  August 10, 2016

Although most systemic juvenile idiopathic arthritis patients don’t develop macrophage activation syndrome (MAS), the approximately 10% who do have this serious complication can experience widespread, massive inflammation, debilitating symptoms and even death. To improve understanding of MAS among physicians and advance efforts to develop effective therapies to treat it, a panel of 28 international pediatric…

Filed under:ConditionsResearch Rheum Tagged with:criteriaDiagnosisJuvenile idiopathic arthritismacrophage activation syndromepatient careResearchrheumatologistrheumatologyTreatment

  • « Previous Page
  • 1
  • …
  • 49
  • 50
  • 51
  • 52
  • 53
  • …
  • 68
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences